Recent News for PLX - Protalix BioTherapeutics, Inc.

Date Title
Apr 7 PLX: Target Action Date Four Weeks Away
Apr 2 Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Mar 30 Protalix BioTherapeutics (PLX) CEO, Dror Bashan on Q4 2020 Results - Earnings Call Transcript
Mar 30 Protalix BioTherapeutics stock up after FY revenue beat
Mar 30 Protalix BioTherapeutics EPS beats by $0.12, beats on revenue
Mar 30 Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results
Mar 30 Protalix Biotherapeutics, Inc. to Host Earnings Call
Mar 30 Earnings Scheduled For March 30, 2021
Mar 27 The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week
Mar 22 Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021
Mar 4 Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Feb 24 PLX: A Busy Month
Feb 23 Protalix's PRX–102 Monthly Treatment Shows Benefit In Fabry Disease
Feb 23 Protalix Bio up 6% on positive PRX–102 data in Fabry disease
Feb 23 The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
Feb 23 Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
Feb 22 Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Is About To Turn The Corner
Feb 18 Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds
Feb 12 The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed
Feb 12 Protalix BioTherapeutics Raises $35M Via Equity At 21% Discount
Feb 12 Protalix Bio plummets 17% on capital raise
Feb 12 Protalix BioTherapeutics Announces Pricing of its Upsized Public Offering of Common Stock
Feb 11 Protalix announces 6.5M proposed public offering
Feb 11 Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock
Feb 11 Protalix BioTherapeutics Perks Up On Alidornase Alfa Licensing Pact In Respiratory Conditions
Back to the Main PLX Page...